BRAF mutation in cytologically indeterminate thyroid nodules: after reclassification of a variant thyroid carcinoma
Open Access
- 1 February 2019
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 1465-1473
Abstract
Purpose: Fine-needle aspiration biopsy (FNAB) is regarded by the Bethesda system as the gold-standard investigation for stratifying the risk of malignancy of a thyroid nodule. However, some limitations affect the adequacy of the obtained materials, resulting in 30% of the cytological results remaining in the indeterminate category. We aimed to investigate the diagnostic value of the BRAF mutation in cytologically indeterminate thyroid nodules after the reclassification of a variant thyroid carcinoma. Patients and methods: In this prospective diagnostic study, 76 patients with FNAB findings of atypia of undetermined significance (AUS) and suspicious for malignancy (SUS) were included. The BRAF V600 mutation from FNAB was confirmed by a PCR-based method (Sanger sequencing combined with allele-specific real-time PCR techniques) and immunohistochemistry (IHC). Pathological specimens and features, including noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), were reviewed and compared to the FNAB results. Results: Using the PCR-based method, the BRAF mutation was positive in 13/76 cases (17.1%), with the diagnostic values of 16.7% sensitivity, 100% specificity, 100% positive predictive value (PPV), and 82.8% negative predictive value (NPV) in the AUS compared to 73.3% sensitivity, 100% specificity, 100% PPV, and 20% NPV in the SUS. For the IHC technique, only 20 of the 76 cytological specimens were qualified for testing. The BRAF mutation was positive in 13/20 cases, with the diagnostic values of 100% sensitivity, 63.6% specificity, 42.9% PPV, and 100% NPV in the AUS compared to 100% sensitivity and PPV in the SUS. The BRAF mutation was not found in the pathological reports for NIFTP. Conclusion: The malignancy rate is high in our data, with specific and acceptable accuracy rates for the BRAF mutation from FNAB found by using the PCR-based method. NIFTP has been introduced after the pathological reclassification. Molecular diagnosis might be useful to establish the nature of the disease.Keywords
This publication has 40 references indexed in Scilit:
- Pre-analytic steps for molecular testing on thyroid fine-needle aspirations: The goal of good resultsCytojournal, 2013
- Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patientsMedical Oncology, 2013
- The changing face of thyroid cancer in a population‐based cohortCancer Medicine, 2013
- Molecular pathogenesis and mechanisms of thyroid cancerNature Reviews Cancer, 2013
- Impact of Mutational Testing on the Diagnosis and Management of Patients with Cytologically Indeterminate Thyroid Nodules: A Prospective Analysis of 1056 FNA SamplesThe Journal of Clinical Endocrinology & Metabolism, 2011
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011
- Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patternsLaboratory Investigation, 2010
- BRAF Mutation Testing of Thyroid Fine-Needle Aspiration Biopsy Specimens for Preoperative Risk Stratification in Papillary Thyroid CancerJournal of Clinical Oncology, 2009
- Molecular Testing for Mutations in Improving the Fine-Needle Aspiration Diagnosis of Thyroid NodulesThe Journal of Clinical Endocrinology & Metabolism, 2009
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005